What is Inositol?

The inositols, myo-inositol (MI) and D-chiro-inositol (DCI), have been studied extensively in endocrine as well as in metabolic disorders. Myo-inositol (MI) is commonly found in foods such as: fruits, beans, grains, and nuts. Fresh vegetables and fruits contain more MI than frozen, canned, or salt-free preparations. Supplementation doses are much higher then what you would find in food and the therapeutic levels needed may not be achieved from diet alone.

Earlier labeled as a B Vitamin, and as a pseudovitamin, this isomer of glucose is an active participant in multiple cellular processes and structures. In its free form, as isomers or as phosphate derivatives, it contributes to:

• ion channel permeability

• mRNA export and translation

• cytoskeleton remodeling

• stress response

• metabolic homeostasis

• oocyte maturation

• sperm function

• cognitive function

• prominent component of cytoplasmic membranes

Myo-inositol for Women in Midlife with Metabolic Syndrome

Many women notice that around the menopausal transition, it becomes harder to keep blood sugar, weight, and cholesterol in a healthy range. Estrogen decline is linked with increased insulin resistance and a higher risk of metabolic syndrome, even when diet and exercise habits have not changed dramatically. Human clinical trials now suggest that inositol, particularly myo-inositol (MI) may support metabolic health in postmenopausal women, although the evidence is still emerging.

Myo-inositol might be considered one of the insulin-sensitizing substances in the treatment of metabolic syndrome. (Santamaria, et al., 2012)

Inositol acts as second messengers in insulin signaling, helping cells respond appropriately when insulin binds to its receptor. Because of this role, researchers have looked at whether supplemental myo-inositol can improve insulin sensitivity, blood sugar, and cardiometabolic markers in midlife women, especially those already diagnosed with metabolic syndrome.

Why Metabolic Health Gets Harder in Midlife

Metabolic syndrome is a cluster of risk factors that includes abdominal obesity, high blood pressure, elevated fasting glucose, high triglycerides, and low HDL cholesterol. It becomes more common after menopause, and this shift is partly driven by changes in estrogen and body fat distribution that promote insulin resistance. For many women, this shows up as stubborn visceral/belly fat ("Meno-belly"), rising fasting glucose or HbA1c, and changes in cholesterol despite an otherwise similar lifestyle.

This is why midlife and postmenopausal women are often highly motivated to look for tools beyond diet and exercise to support insulin sensitivity. Inositol has become popular in Polycystic Ovarian Syndrome (PCOS) recently renamed to Polyendocrine Metabolic Ovarian Syndrome (PMOS), and clinicians have begun asking if some of that benefit might translate to women in their 40s, 50s, and beyond. The key question is: what do human trials in this age group actually show?

Myo-Inositol in Postmenopausal Women

12‑month randomized trial in postmenopausal women with metabolic syndrome

One of the most important human studies looked exclusively at postmenopausal women with metabolic syndrome. In this 12‑month randomized, placebo-controlled trial, 80 outpatient postmenopausal women were put on a low-energy diet and then assigned to either myo-inositol 2 g twice daily (4 g/day) or placebo. All women were followed for one year and had fasting glucose, insulin, HOMA-IR, triglycerides, total and HDL cholesterol, blood pressure, BMI, and waist circumference measured at baseline and at 12 months.

"After 12 months of treatment, all the parameters studied showed a significant improvement in the myo-inositol group compared to the control group. At the end of the study, in the myo-inositol group, the number of women without metabolic syndrome was eight (20%) whereas, in the control group, only one woman no longer had the metabolic syndrome after 12 months of diet." (Santamaria, et al., 2012)

Studies have concluded that inositol, particularly myo-inositol, have a potential role in helping to maintain metabolic health in postmenopausal women, with strongest evidence in metabolic syndrome and insulin‑mediated conditions.

Is Myo-Inositol a replacement for medications?

For women in midlife, myo‑inositol is not a magic pill, but it can be a valuable tool used as part of a comprehensive plan that includes nutrition, movement, stress support, and (when needed) hormone therapy and/or conventional medications. Myo-inositol is not a replacement for medications that lower blood sugar, HbA1C and for lipid lowering drugs.

If you’re navigating perimenopause or postmenopause and concerned about blood sugar, cholesterol, or stubborn weight gain, talk to your healthcare provider about whether myo‑inositol could be an appropriate addition to your midlife metabolic toolbox

To your best health,

Dr. Amy Tung, ND,MSCP

Naturopathic Doctor | Menopause Society Certified Practitioner

References:

Giordano D, Corrado F, Santamaria A, Quattrone S, Pintaudi B, Di Benedetto A, D'Anna R. Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a perspective, randomized, placebo-controlled study. Menopause. 2011 Jan;18(1):102-4. doi: 10.1097/gme.0b013e3181e8e1b1. PMID: 20811299.

Kalra S, Kalra B. Inositols in Midlife. J Midlife Health. 2018 Jan-Mar;9(1):36-38. doi: 10.4103/jmh.JMH_52_16. PMID: 29628727; PMCID: PMC5879846.

Santamaria A, Giordano D, Corrado F, Pintaudi B, Interdonato ML, Vieste GD, Benedetto AD, D'Anna R. One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome. Climacteric. 2012 Oct;15(5):490-5. doi: 10.3109/13697137.2011.631063. Epub 2011 Dec 23. PMID: 22192068.